
In the final portion of our discussion with Kimberly Kue-Tsemo, PharmD, she explores the key developments that could be the most significant push toward reducing pharmacy deserts.
New antivirals and updated guidelines offer opportunities for R.Ph. management of this drug-intensive disease






